|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 72.82 USD | +0.03% |
|
-.--% | +0.96% |
| 05-20 | Pharma sector doubles down on AI amid hopes of slashing costs, timelines | RE |
| 05-15 | Leerink Partners Initiates Coverage on Atrium Therapeutics With Outperform Rating, $25 PT | MT |
| Market Cap | 11.3B 9.91B 9.15B 8.45B 16.02B 1,082B 16.34B 110B 42.73B 529B 42.43B 41.5B 1,838B | P/E 2024 |
-10.1x | P/E 2025 | -14.5x |
|---|---|---|---|---|---|
| Enterprise Value | 9.65B 8.46B 7.81B 7.22B 13.69B 924B 13.96B 93.94B 36.5B 452B 36.24B 35.45B 1,570B | EV / Sales 2024 |
181x | EV / Sales 2025 | 492x |
| Free-Float |
96.26% | Yield 2024 * |
-
| Yield 2025 | - |
Last Transcript: Avidity Biosciences, Inc.
| 1 day | +0.03% | ||
| 6 months | +0.62% | ||
| Current year | +0.96% |
| Current year | 72 |  | 73.06 |
| 1 year | 29.33 | | 73.06 |
| 3 years | 4.82 | | 73.06 |
| 5 years | 4.82 | | 73.06 |
| 10 years | 4.82 | | 73.06 |
| Manager | Title | Age | Since |
|---|---|---|---|
John McKenna
PSD | President | - | 2026-02-26 |
Eduard Marti
TRE | Treasurer | - | 2026-02-26 |
Jaime S. Huertas
SEC | Corporate Secretary | - | 2026-02-26 |
| Director | Title | Age | Since |
|---|---|---|---|
Jaime S. Huertas
BRD | Director/Board Member | - | 2026-02-26 |
Eduard Marti
BRD | Director/Board Member | - | 2026-02-26 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 02-26 | Issuer sale | Director | 110,073 | 0.0766% | ||
| 02-26 | Issuer sale | General Counsel | 302,054 | 0.2103% | ||
| 02-26 | Issuer sale | Chief Technology Officer | 547,865 | 0.3814% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.03% | -.--% | +152.85% | +559.60% | 11.3B | |
| -1.68% | +6.41% | +21.36% | -5.49% | 68.8B | |
| -2.01% | -3.57% | +46.21% | +217.06% | 55.21B | |
| -4.15% | +36.30% | +36.30% | +36.30% | 43.46B | |
| +0.27% | +8.33% | -49.87% | -53.43% | 41.18B | |
| -6.58% | +3.19% | +129.90% | -39.22% | 31.65B | |
| -1.35% | -2.86% | +51.53% | -27.64% | 30.37B | |
| -0.97% | +3.12% | +73.43% | +89.63% | 23.58B | |
| -1.15% | +8.29% | +4.42% | +184.96% | 19.33B | |
| -1.33% | +1.11% | +66.11% | +131.83% | 17.16B | |
| Average | -1.88% | +3.37% | +53.22% | +109.36% | 34.2B | |
| Weighted average by Cap. | -2.06% | +3.43% | +40.64% | +67.76% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 10.9M 9.56M 8.82M 8.15M 15.46M 1.04B 15.76M 106M 41.22M 511M 40.92M 40.02M 1.77B | 18.76M 16.45M 15.19M 14.03M 26.6M 1.8B 27.13M 183M 70.94M 879M 70.43M 68.89M 3.05B |
| Net income | -322M -283M -261M -241M -457M -30.86B -466M -3.14B -1.22B -15.1B -1.21B -1.18B -52.43B | -685M -600M -554M -512M -971M -65.55B -990M -6.66B -2.59B -32.08B -2.57B -2.51B -111B |
| Net Debt | -1.49B -1.31B -1.21B -1.12B -2.12B -143B -2.16B -14.55B -5.65B -70.04B -5.61B -5.49B -243B | -1.65B -1.45B -1.33B -1.23B -2.34B -158B -2.38B -16.04B -6.23B -77.2B -6.19B -6.05B -268B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- RNA Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
